A detailed history of Logos Global Management LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Logos Global Management LP holds 500,000 shares of BCYC stock, worth $10 Million. This represents 1.5% of its overall portfolio holdings.

Number of Shares
500,000
Holding current value
$10 Million
% of portfolio
1.5%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.58 - $27.24 $9.79 Million - $13.6 Million
500,000 New
500,000 $11.3 Million
Q2 2023

Aug 14, 2023

SELL
$18.95 - $28.67 $4.36 Million - $6.59 Million
-230,000 Reduced 30.67%
520,000 $13.3 Million
Q1 2023

May 15, 2023

SELL
$20.02 - $31.37 $13.7 Million - $21.5 Million
-685,000 Reduced 47.74%
750,000 $16 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $11.5 Million - $18.6 Million
-565,000 Reduced 28.25%
1,435,000 $42.5 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $5.25 Million - $8.53 Million
300,000 Added 17.65%
2,000,000 $46.5 Million
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $9.71 Million - $35.2 Million
750,000 Added 78.95%
1,700,000 $28.5 Million
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $3.21 Million - $4.76 Million
80,000 Added 9.2%
950,000 $41.7 Million
Q4 2021

Feb 14, 2022

SELL
$41.7 - $61.14 $25.2 Million - $37 Million
-605,000 Reduced 41.02%
870,000 $53 Million
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $21.2 Million - $33.6 Million
760,000 Added 106.29%
1,475,000 $61.3 Million
Q2 2021

Aug 16, 2021

SELL
$27.0 - $32.28 $2.3 Million - $2.74 Million
-85,000 Reduced 10.63%
715,000 $21.7 Million
Q1 2021

May 17, 2021

BUY
$19.12 - $30.25 $15.3 Million - $24.2 Million
800,000 New
800,000 $23.9 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $594M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Logos Global Management LP Portfolio

Follow Logos Global Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.